Helius Medical Technologies To Present At 93rd Annual ACRM Conference Plenary Session

NEWTOWN, Pa.--(BUSINESS WIRE)--Helius Medical Technologies, Inc. (TSX: HSM, OTCQB: HSDT) (“Helius” or the “Company”) is pleased to announce that the American Congress of Rehabilitation Medicine (ACRM) has accepted a submission from Helius for a panel discussion – “PoNS™ Therapy: non-invasive investigational cranial nerve neuromodulation to augment therapeutic interventions” - at ACRM’s 93^rd Annual Conference (October 30 to November 4, 2016, in Chicago, IL)

“PoNS™ Therapy: non-invasive investigational cranial nerve neuromodulation to augment therapeutic interventions”

Helius is currently enrolling subjects in a pivotal trial for the treatment of balance disorder resulting from Traumatic Brain Injury (TBI) using the investigational PoNS™ Therapy. The ACRM Conference represents an excellent venue to present the scientific basis supporting PoNS Therapy as well as to summarize historical and evolving clinical data. Dr. Jonathan Sackier, Helius’ Chief Medical Officer, will be one of the presenters at the symposium. “Any innovative therapy that has the potential to impact a large patient pool, representing a significant unmet medical need, must be introduced at an early stage to key opinion leaders and practitioners focused on innovation in patient care,” said Mr. Sackier. “We are delighted that ACRM has accepted our submission and are further enthused that this symposium is well timed to coincide with our clinical trial activities.”

About ACRM: ACRM States that its mission is: “IMPROVING LIVES of those with disabling conditions through interdisciplinary rehabilitation research,” and that it “curates and disseminates world-class rehabilitation research in print (via its journal the Archives of Physical Medicine & Rehabilitation), in person (at the ACRM Conference), and online.” For more information, please visit ACRM.org.

About PoNS™ Therapy

The Portable Neuromodulation Stimulator (PoNS™) is an investigational non-invasive device designed to deliver neurostimulation through the tongue. PoNS™ Therapy combines the use of the device with physical therapy and is currently being evaluated in a multicenter clinical trial for the treatment of balance disorder for subjects with mild to moderate Traumatic Brain Injury. A description of the trial is available at clinicaltrials.gov.

About Helius Medical Technologies, Inc.

Helius Medical Technologies is a medical technology company focused on neurological wellness. Helius seeks to develop, license and acquire unique and non-invasive platform technologies that amplify the brain’s ability to heal itself. Helius intends to file for FDA clearance for the PoNS™ device. For more information, please visit www.heliusmedical.com.

The Toronto Securities Exchange has not reviewed and does not accept responsibility for the adequacy or accuracy of the content of this news release.

Cautionary Disclaimer Statement:

Certain statements in this news release are not based on historical facts and constitute forward-looking statements or forward-looking information within the meaning of the U.S. Private Securities Litigation Reform Act of 1995 and Canadian securities laws (“forward-looking statements”).

All statements other than statements of historical fact included in this news release are forward-looking statements that involve risks and uncertainties. Such forward-looking statements include, among others, statements regarding ongoing or planned clinical research, expected future development timelines, regulatory approvals, business initiatives and objectives and use of proceeds from financings or other business initiatives.

Forward-looking statements are often identified by terms such as “will”, “may”, “should”, “anticipate”, “expects” and similar expressions.

There can be no assurance that such statements will prove to be accurate and actual results and future events could differ materially from those anticipated in such statements. Important factors that could cause actual results to differ materially from the Company’s expectations include the failure of the Company to achieve its business objectives and other risks detailed from time to time in the filings made by the Company with securities regulators.

The reader is cautioned that assumptions used in the preparation of any forward-looking statements may prove to be incorrect. Events or circumstances may cause actual results to differ materially from those predicted, as a result of numerous known and unknown risks, uncertainties, and other factors, many of which are beyond the control of the Company. The reader is cautioned not to place undue reliance on any forward-looking statement. Such information, although considered reasonable by management at the time of preparation, may prove to be incorrect and actual results may differ materially from those anticipated. Forward-looking statements contained in this news release are expressly qualified by this cautionary statement. Risks and uncertainties about the Company’s business are more fully discussed in the Company’s disclosure materials, , its Annual Report on Form 10-K filed with the United States Securities and Exchange Commission and the Canadian securities regulators and which can be obtained from either at www.sec.gov or www.sedar.com.

The forward-looking statements contained in this news release are made as of the date of this news release and the Company assumes no obligation to update any forward-looking statement or to update the reasons why actual results could differ from such statements except to the extent required by law.